LONDON — GSK stated Wednesday it could buy an experimental liver illness medication from Boston Prescribed drugs for $1.2 billion upfront, looking for to construct up its pipeline of future medicines.
The drug, known as efimosfermin, is in growth to deal with a liver situation known as MASH, a sign that quite a few drugmakers are pursuing. The once-monthly drug can also be being thought of as a remedy for alcohol-related liver illness.
The deal for efimosfermin, which GSK described as prepared for Part 3 research, contains one other $800 million if sure milestones are met.
This text is unique to STAT+ subscribers
Unlock this text — plus day by day protection and evaluation of the pharma business — by subscribing to STAT+.
Have already got an account? Log in
To learn the remainder of this story subscribe to STAT+.
